Mavacamten: Practical Answers for the Clinician and New Questions From the MAVA-Long-Term Extension Study

JACC Heart Fail. 2024 Jan;12(1):178-181. doi: 10.1016/j.jchf.2023.08.034.

Authors

Enrico Ammirati¹, Guglielmo Gallone²

Affiliations

¹ De Gasperis Cardio Center, Transplant Center, Niguarda Hospital, Milano, Italy; Department of Health Sciences, University of Milano-Bicocca, Monza, Italy. Electronic address: enrico.ammirati@ospedaleniguarda.it.
² Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Department of Medical Sciences, University of Turin, Italy.

PMID: 38176783
DOI: 10.1016/j.jchf.2023.08.034

No abstract available

Keywords: Mavacamten; efficacy; hypertrophic cardiomyopathy; myosin inhibitor; safety.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzylamines
Cardiomyopathy, Hypertrophic*
Heart Failure* / drug therapy
Humans
Longitudinal Studies
Uracil

Substances

MYK-461
Benzylamines
Uracil